(DSGN) Design Therapeutics - Overview
Stock: GeneTAC, Friedreich, Ataxia, Myotonic, Dystrophy
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 87.2% |
| Relative Tail Risk | -11.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.36 |
| Alpha | 95.96 |
| Character TTM | |
|---|---|
| Beta | 0.975 |
| Beta Downside | 0.924 |
| Drawdowns 3y | |
|---|---|
| Max DD | 75.55% |
| CAGR/Max DD | 0.18 |
Description: DSGN Design Therapeutics January 01, 2026
Design Therapeutics, Inc. (NASDAQ:DSGN) is a clinical-stage biotech that leverages its GeneTAC platform to create small-molecule drugs targeting nucleotide-repeat expansion disorders. Its pipeline focuses on four monogenic diseases-Friedreich’s Ataxia, Myotonic Dystrophy Type-1, Fuchs Endothelial Corneal Dystrophy, and Huntington’s Disease-each of which involves mitochondrial dysfunction or neuro-muscular degeneration. The company, incorporated in 2017 and based in Carlsbad, California, is positioned as a pure-play genetics-focused therapeutic developer within the U.S. biotechnology sub-industry.
As of the most recent 10-Q, DSGN reported a cash balance of roughly $55 million, giving it an estimated 12-month runway at current burn rates (~$4.5 million per quarter). The market values the firm at approximately $140 million, reflecting a price-to-sales multiple of ~12× for its pre-revenue pipeline-a premium that aligns with investor appetite for rare-disease assets. Sector-wide, the gene-repeat expansion niche has attracted $1.2 billion of venture capital in the past 12 months, and the FDA’s recent guidance on accelerated pathways for neurodegenerative indications could shorten time-to-market for DSGN’s lead candidates.
For a deeper quantitative view, consider reviewing ValueRay’s analyst platform to explore DSGN’s financials and comparable peer metrics.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -67.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.25 > 0.02 and ΔFCF/TA -7.01 > 1.0 |
| NWC/Revenue: 33.6k% < 20% (prev 29.8k%; Δ 3839 % < -1%) |
| CFO/TA -0.25 > 3% & CFO -52.3m > Net Income -67.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 18.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (57.0m) vs 12m ago 0.58% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.25% > 50% (prev 0.32%; Δ -0.07% > 0%) |
| Interest Coverage Ratio: -12.74 > 6 (EBITDA TTM -72.6m / Interest Expense TTM -5.75m) |
Altman Z'' -15.00
| A: 0.93 (Total Current Assets 209.0m - Total Current Liabilities 11.2m) / Total Assets 211.8m |
| B: -1.33 (Retained Earnings -281.0m / Total Assets 211.8m) |
| C: -0.31 (EBIT TTM -73.2m / Avg Total Assets 236.7m) |
| D: -23.29 (Book Value of Equity -280.6m / Total Liabilities 12.1m) |
| Altman-Z'' Score: -24.73 = D |
Beneish M -3.36
| DSRI: 1.67 (Receivables 1.38m/1.18m, Revenue 588.0k/838.0k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.0 (AQ_t 0.0 / AQ_t-1 0.00) |
| SGI: 0.70 (Revenue 588.0k / 838.0k) |
| TATA: -0.07 (NI -67.4m - CFO -52.3m) / TA 211.8m) |
| Beneish M-Score: -3.36 (Cap -4..+1) = AA |
What is the price of DSGN shares?
Over the past week, the price has changed by -1.34%, over one month by +11.87%, over three months by +38.22% and over the past year by +141.08%.
Is DSGN a buy, sell or hold?
- StrongBuy: 0
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DSGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14.4 | 40.2% |
| Analysts Target Price | 14.4 | 40.2% |
| ValueRay Target Price | 11.5 | 11.6% |
DSGN Fundamental Data Overview February 03, 2026
P/B = 3.0148
Revenue TTM = 588.0k USD
EBIT TTM = -73.2m USD
EBITDA TTM = -72.6m USD
Long Term Debt = 1.74m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 866.0k USD (from shortTermDebt, last quarter)
Debt = 1.74m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -13.3m USD (from netDebt column, last quarter)
Enterprise Value = 377.4m USD (581.6m + Debt 1.74m - CCE 206.0m)
Interest Coverage Ratio = -12.74 (Ebit TTM -73.2m / Interest Expense TTM -5.75m)
EV/FCF = -7.20x (Enterprise Value 377.4m / FCF TTM -52.4m)
FCF Yield = -13.89% (FCF TTM -52.4m / Enterprise Value 377.4m)
FCF Margin = -8913 % (FCF TTM -52.4m / Revenue TTM 588.0k)
Net Margin = -11.5k% (Net Income TTM -67.4m / Revenue TTM 588.0k)
Gross Margin = unknown ((Revenue TTM 588.0k - Cost of Revenue TTM 15.0m) / Revenue TTM)
Tobins Q-Ratio = 1.78 (Enterprise Value 377.4m / Total Assets 211.8m)
Interest Expense / Debt = 7.40% (Interest Expense 129.0k / Debt 1.74m)
Taxrate = 21.0% (US default 21%)
NOPAT = -57.8m (EBIT -73.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 18.71 (Total Current Assets 209.0m / Total Current Liabilities 11.2m)
Debt / Equity = 0.01 (Debt 1.74m / totalStockholderEquity, last quarter 199.7m)
Debt / EBITDA = 0.18 (negative EBITDA) (Net Debt -13.3m / EBITDA -72.6m)
Debt / FCF = 0.25 (negative FCF - burning cash) (Net Debt -13.3m / FCF TTM -52.4m)
Total Stockholder Equity = 220.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.49% (Net Income -67.4m / Total Assets 211.8m)
RoE = -30.56% (Net Income TTM -67.4m / Total Stockholder Equity 220.7m)
RoCE = -32.90% (EBIT -73.2m / Capital Employed (Equity 220.7m + L.T.Debt 1.74m))
RoIC = -26.20% (negative operating profit) (NOPAT -57.8m / Invested Capital 220.7m)
WACC = 9.50% (E(581.6m)/V(583.3m) * Re(9.51%) + D(1.74m)/V(583.3m) * Rd(7.40%) * (1-Tc(0.21)))
Discount Rate = 9.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.71%
Fair Price DCF = unknown (Cash Flow -52.4m)
EPS Correlation: 37.57 | EPS CAGR: 29.38% | SUE: 4.0 | # QB: 1
Revenue Correlation: 17.73 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.35 | Chg30d=-0.010 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-1.30 | Chg30d=+0.016 | Revisions Net=-1 | Growth EPS=+0.5% | Growth Revenue=+0.0%